Five things for the weekend
- Special CoverageSpecial Coverage: The State of BiotechOur state of the union for biotech as the year turns: share prices are falling alongside the AI trade, while FDA has approved 55 new drugs this year. We test the thesis against its strongest alternative and close with a playbook for CEOs, boards and allocators before JPM. FDA novel approvals, 2026#
- Must readFDA turned down Capricor’s deramiocel in Duchenne muscular dystrophy a second time.FDA’s own statement cites “serious data integrity violations” in HOPE-3; Capricor says both of its trials met their primary endpoints.Match NCT06356311 registers overall survival as the single primary outcome, with progression-free survival, response rate and duration of response by blinded central review as secondaries, and 473 enrolled;#
- Must readMerck says sac-TMT improved overall survival in third-line gastroesophageal cancer in the Phase 3 TroFuse-015.Progression-free survival, a secondary endpoint, wasn’t met, and no hazard ratio was released.Partial NCT04585750 registers the Phase 2 primaries as response rate in the ovarian cohort and across all cohorts, both as assessed by independent review; the release reports investigator-assessed responses, #
- Know itPMV’s rezatapopt drew responses in 48% of 65 women with platinum-resistant or refractory ovarian cancer.It’s a single-arm trial with investigator-assessed responses; PMV plans an accelerated approval filing in the first quarter of 2027.#
- Know itFDA will miss Savara’s 11.22 goal date for molgramostim in autoimmune PAP.The review continues, with no new date given.#
- ScanFriday’s money was closings, not new deals: Avenzo’s $215M placement and SELLAS’s $172.5M offering.The Sanofi and Insmed report remains unconfirmed by either company.#
Bright spot
In the randomized RT CHARM trial, 16 radiation sessions after mastectomy and reconstruction were noninferior to 25 on complications at 24 months, per ASCO Post’s report: nine fewer trips to the clinic.
Verified today #
Claim Check #
| Readout | Registry says | Headline says | Verdict |
|---|---|---|---|
| Sac-TMT TroFuse-015 · Merck NCT06356311 | Phase 3. Primary: overall survival. Secondaries include PFS by blinded central review. N=473. | Met overall survival at final analysis; PFS secondary not met; no hazard ratio released | Match |
| Rezatapopt PYNNACLE · PMV NCT04585750 | Phase 1/2. Phase 2 primaries: response rate by independent review, ovarian cohort and all cohorts. 300 planned; recruiting. | Investigator-assessed response 48% (31 of 65) in platinum-resistant or refractory ovarian cancer; 36% of 168 overall | Partial |
Calendar #
| Date | Event | Who | Confirmed at |
|---|---|---|---|
| 2026-11-23 | Conference call on the deramiocel complete response letter, 8:30 am ET | Capricor | Company |
| 2026-11-23 | KT-621 BROADEN2 Phase 2b results in atopic dermatitis | Kymera | Company |
| 2026-11-25 | GDP, third quarter second estimate, and corporate profits | BEA | Gov |
| 2026-11-25 | Personal income and outlays for October, including PCE prices | BEA | Gov |
| 2026-11-25 | Beige Book | Federal Reserve | Fed |
| 2026-11-26 | Thanksgiving: federal offices closed | Federal Reserve | Fed |
| 2026-11-27 | NDA goal date, priority review: BBP-418 in LGMD2I/R9 | BridgeBio | Company |
| 2026-11-28 | NDA goal date, priority review: D-PLEX100 in colorectal surgery | PolyPid | Company |
| 2026-11-29 | RSNA Annual Meeting opens, Chicago | RSNA | Organizer |
| 2026-11-30 | Goal date, priority review: giredestrant adjuvant (lidERA) | Roche | Company |
| 2026-11-30 | BLA goal date, accelerated approval: povetacicept in IgA nephropathy | Vertex | Company |
| 2026-11-30 | NDA goal date, priority review: bezuclastinib with sunitinib in GIST | Cogent | Company |
| 2026-11-30 | Deadline to publish negotiated prices for the 15 drugs selected for 2028 | CMS | CMS |
Money Map #
| Week | Deals | Total | Largest deals |
|---|---|---|---|
| 10.19 to 10.25 | 12 | $2,217M | Disc Medicine, Lycia, Arcus |
| 10.26 to 11.01 | 11 | $1,393M | Dren Bio, Corxel US, Rapport |
| 11.02 to 11.08 | 11 | $679M | T-Therapeutics, Precision BioSciences, Alethio |
| 11.09 to 11.15 | 17 | $1,286M | Windward Bio, Vir, Prime Medicine |
| 11.16 to 11.22 | 8 | $5,540M | Isomorphic Labs ($5,000M), SELLAS ($150M), Marrow ($120M) |
Therapeutic Area Pulse #
| Therapeutic area | Evidence | Coverage | Items | Confidence | What drove it |
|---|---|---|---|---|---|
| Oncology | +1.2 | +0.4 | 11 · 16 | HIGH | Approvals for Wilserdly and Nelkarmi and survival wins for SELLAS and Merck’s sac-TMT, against Merck’s nemtabrutinib stop and coverage of Summit’s rejection letter |
| Immunology & inflammation | -0.2 | 0.0 | 4 · 6 | MED | Livsayis approved in myasthenia gravis, against two eczema misses, Aclaris’s bosakitug and Celldex’s barzolvolimab |
| Metabolic & obesity | · | 0.0 | 0 · 3 | LOW | Seawolf’s $100M launch not scored; coverage only: lower-dose CagriSema, the compounded GLP-1 debate and trial design |
| Neuroscience | -0.5 | 0.0 | 4 · 7 | MED | Helus’s Phase 3 win in depression, against Actinogen’s Phase 2b/3 miss and AriBio’s overall-population miss in Alzheimer’s |
| Cardiovascular & renal | QUIET | QUIET | 0 · 1 | · | Fewer than three scored items this week |
| Rare & genetic | +0.4 | +0.3 | 5 · 7 | HIGH | Two approvals, Lembaz and Infilbray, against FDA’s second rejection of Capricor’s deramiocel and the missed Savara date |
| Gene, cell & editing | +1.0 | +1.0 | 1 · 3 | LOW | Pfizer’s in vivo CAR-T license from Starna and coverage of a profitable genetic medicines business |
| Infectious disease & vaccines | QUIET | QUIET | 1 · 0 | · | Fewer than three scored items this week |
| Other & platform | +1.0 | +1.0 | 2 · 2 | LOW | Isomorphic’s $5B round and Lilly’s Stipple pact |
Download the full briefPDF, 33 pages
Track record: our calls, graded in public · corrections log
Want this by email? Join Mind Club. It's complimentary.